openwiki-wiki/sources/web-search.md

Web Search Evidence

Connector: web-search-1 (Tavily). This page records compact, relevant evidence from the 2026-07-26 pull; search results are discovery leads, not vendor-confirmed announcements.

2026-07-26 pull

3D spheroid automation and assay standardization — source-backed

• Nature, published 2026-07-21: Automation of 3D liver spheroid generation and acetaminophen dose–response on the MO:BOT enhances assay robustness and precision. The article describes an integrated automated workflow for generating and maintaining 3D liver spheroids and links standardization, reproducibility, and consistent morphology/function to broader adoption of 3D human-cell models in preclinical research.
• Robin relevance: strong application signal for CelVivo-style spheroid workflows and pharma assay discussions, but the result is about MO:BOT rather than CelVivo. Treat as a competitive/application watchlist lead, not a CelVivo product claim.
• Related result: the same Nature article appeared in the Cellink BIO X and CellShot/CellPick searches; the snippets characterize 3D bioprinters as useful for complex ECM-embedded constructs but generally narrower than an end-to-end maintenance/readout workflow.

Organ-on-chip and preclinical translation — watchlist

• Nature, published 2026-07-23: Engineering human Gut-on-a-Chip culturomics for predictive pharmacomicrobiomics of first-pass metabolism. Tavily's result highlights intestinal first-pass metabolism and pharmacokinetic differences for orally administered drugs.
• GeneOnline, published 2026-07-26: Next-Gen Preclinical Translation: Non-Animal Methods, Humanized Mouse Models, and AI Integration. The snippet frames organ-on-a-chip, NAMs, humanized models, and predictive AI as part of current preclinical translation work.
• These are relevant to Robin's organ-on-chip/pharma lane, but the pull provides no customer, vendor, or regulatory action. Keep as watchlist evidence.

3Brain / neuroscience search lane — no direct product confirmation

• The strongest result was a 2026-07-24 Scientific Reports article on a portable semi-dry EEG device for brain-computer-interface applications (Nature link); it does not identify 3Brain CorePlate or MEA chips. Do not promote it as 3Brain evidence.

Cellink, Femtobiomed, and workflow tooling

• The pull produced no credible direct Cellink BIO X/BIONOVA X/Lumen X announcement, no CellShot/CellPick/TriArm result, and no Hermes/OpenWiki/RAGFlow ecosystem result.
• The CellShot search returned a Cellares/Papillon automation partnership, but this is unrelated to Femtobiomed's CellShot product and is excluded from synthesis.

Evidence handling

• Search results are single-source discovery evidence; vendor-specific claims require direct vendor or independent corroboration before being labeled confirmed or source-backed.
• Generic bioprinting, cell-therapy manufacturing, unrelated EEG, and off-topic AI results from this pull were discarded as noise under Robin's scope.

Source coverage

• Fetched: 2026-07-26T17:39:11Z
• Queries: 10
• Instance: web-search-1
• Raw evidence: ~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json

---

2026-07-26 18:07 pull

Second Tavily pull on the same day (same 10-query lane). Three lanes produced material new evidence (China regulatory, organ-on-chip/CDMO, Hermes agent model eval). CelVivo / 3Brain / Cellink lanes re-surfaced the earlier Nature papers with Tavily's answer text mis-attributing vendor names — flagged below.

China CDE cell & gene therapy classification — source-backed

• cisema.com, 2026-07-24: China CDE Defines Classification Rules for Cell & Gene Therapy Drugs. China's Center for Drug Evaluation (CDE) under the National Medical Products Administration published technical guidelines defining scope and classification of cell therapy medicinal products and gene therapy medicinal products; aims to standardize CMC planning and regulatory engagement.
• Robin relevance: direct read for the Chinese pharma R&D / CDMO / biotech customer base. Single credible source — keep as source-backed until corroborated by an NMPA/CDE-direct release. Promoted to /themes.md row china-cde-cell-gene-therapy-rules-2026 and /commitments.md as a verification item.
• Lighter signals in this lane: Roots Analysis Cell Therapy Manufacturing Market Size 2035 (2026-07-24); Frontiers pilot study of nebulized 3D-cultured MSC-derived extracellular vesicles (2026-07-24); PharmaSalmanac Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes (2026-07-22). Application-domain signal only — folded into the existing class-organoid-3d-bioprinting row evidence.

Organ-on-chip / CDMO collaboration / ADLM 2026 — source-backed

• BioSpace, 2026-07-24: Phillips Medisize to Present Strategies for Scaling Complex In Vitro Diagnostic (IVD) Builds Through Structured CDMO Collaboration at ADLM 2026. Top score (0.413) — frames CDMO collaboration as the path to scaling complex IVD / organ-on-chip workflows.
• BioSpace, 2026-07-24: AcroCyte Therapeutics Awarded ARPA-H Funding to Advance Scalable Human Organoid Technologies. 0.215 score. ARPA-H backing for scalable human-organoid platforms — application-domain signal for CelVivo-class bioreactor positioning.
• Nature, 2026-07-24: Engineering etiology-aligned in vitro models of human vessels. 0.165 score. Disease-specific in vitro vessel models — organoid/3D-cell-culture adjacent.
• BioSpace, 2026-07-23: Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026. 0.151 score. Industry context, not vendor-anchored to Robin's 4 lines.

Hermes Agent best-models eval — source-backed (workflow tooling, low priority)

• haimaker.ai, 2026-07-23: Best Models for Hermes Agent (July 2026): Tested & Ranked. 0.731 score. Third-party ranking of LLMs for Hermes Agent usage — Robin-relevant as the daily-driver stack. Folds into the existing MiniMax-m3 theme row last-seen.
• Reddit, 2026-07-22: What are you USE CASES for Hermes Agent?. 0.424 score. User-driven Hermes use cases; not a vendor-anchored signal.
• Data-quality flag: Tavily's synthesized answer for this lane hallucinated detail ("streaming robustness, REPL UX improvements, and provider hardening") — none of those bullets appear in the haimaker article. Treat Tavily's answer text as untrusted.

CelVivo / 3Brain / Cellink / CellShot lanes — same Nature results, Tavily answer text mis-attributed

• CelVivo ClinoReactor / Cellink BIO X: the Nature MO:BOT liver-spheroid automation paper reappears at score 0.402 (CelVivo lane) and 0.074 (Cellink lane). Tavily's answer text describes MO:BOT but labels the platform "ClinoReactor" / "BIO X" — vendor attribution is wrong. Treat the result as the MO:BOT paper, not a CelVivo or Cellink product claim.
• 3Brain CorePlate MEA: the Nature portable semi-dry EEG device paper reappears at score 0.187. Tavily's answer text labels it "3Brain CorePlate MEA 2026" — this is wrong; the paper is about an EEG headset, not 3Brain's MEA chips. Do not promote as 3Brain evidence.
• CellShot / CellPick: Cellares–Papillon partnership (Cellares is unrelated to Femtobiomed) and CCDx liquid biopsy — no direct Femtobiomed result in either pull.
• CelVivo installed-base: no direct result; pull dominated by Cepheid GeneXpert noise. Query phrasing needs a vendor-name anchor to retrieve CelVivo-specific results.

OpenWiki / RAGFlow / agent-memory-wiki lanes — Tavily recall broken

• "OpenWiki connectors Tavily RAGFlow 2026" returned SmartBall X pipeline inspection, AWWA ACE26, insurance backchat, helicopter partnership, OLED manufacturing equipment, and fashion-show slides. None of the 8 results touches Robin's actual stack (OpenWiki / Gitea / Wiki.js / RAGFlow / NocoDB / SeaFile). Skip until the query is rephrased.
• "Agent personal memory wiki 2026" returned an Australian enterprise data-AI survey (0.403), a LangChain4j self-building-agent experiment (0.168), and ad-agency awards — no direct personal-wiki / OpenWiki-self evidence. Adjacent only.

Source coverage (cumulative)

• Pull 1: fetched 2026-07-26T17:39:11Z — raw ~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json
• Pull 2: fetched 2026-07-26T18:07:27Z — raw ~/.openwiki/connectors/web-search/raw/2026-07-26T18-07-14-335Z/web-search-results.json
• Pull 3: fetched 2026-07-26T18:16:21Z — raw ~/.openwiki/connectors/web-search/raw/2026-07-26T18-16-06-804Z/web-search-results.json
• Queries: pull 1 + pull 2 = 10 queries each; pull 3 = 6 queries (vendor-anchored only)
• Instance: web-search-1

---

2026-07-26 18:16 pull

Third Tavily pull on the same day, after the 2026-07-27 ~/.openwiki/INSTRUCTIONS.md scope was loaded. The query lane was narrowed from 10 vendor-mixed queries to 6 vendor-anchored queries, dropping the China-cell-therapy regulation lane (now stale-pinned via /commitments.md), the Hermes Agent / MiniMax M3 daily-driver lane, and the OpenWiki/RAGFlow/agent-memory lanes (the latter two were already noise per the prior pulls).

Queries and top results

Query	Top hits	Score	Vendor-anchor
CelVivo ClinoReactor spheroid new paper 2026	Nature MO:BOT liver-spheroid automation paper (re-mention); Patient-Derived Tumor Organoids for personalizing cancer treatment; CCDx whole-cell genomic profiling	0.44 / 0.11 / 0.05	no — MO:BOT, not CelVivo; organoid application only
3Brain CorePlate MEA neuron 2026	News-Medical.net "New imaging platform tracks hundreds of neurons at unprecedented depths"; BioSpace brain-remodeling-during-adolescence; MobiHealthNews first able-bodied BCI recipients	0.20 / 0.10 / 0.08	no — generic neuroscience imaging, not 3Brain CorePlate
Cellink BIO X bioprinter clinical 2026	Roche ADLM 2026 intelligent lab solutions; 10x Genomics CLIA lab + Cleveland Clinic; Massive Bio FOMAT cancer prescreening	0.11 / 0.09 / 0.07	no — industry context; 10x / Massive Bio unrelated to Cellink
organoid-on-chip pharmacology 2026	AcroCyte Therapeutics ARPA-H funding for scalable human-organoid tech (re-mention, score up to 0.617 from 0.215); Patient-Derived Tumor Organoids; Nature MO:BOT liver-spheroid	0.62 / 0.41 / 0.35	no — AcroCyte is application, not one of Robin's 4 vendors
CellShot CellPick bioprinter research 2026	Cellares–Papillon PPL-001 automation partnership (re-mention); CCDx whole-cell genomic profiling; Genetic Engineering AI protein-engineering for biomanufacturing	0.17 / 0.14 / 0.08	no — Cellares/Papillon unrelated to Femtobiomed
lab automation assay workflow news 2026	Roche ADLM 2026; Nature MO:BOT liver-spheroid; Cepheid third-generation GeneXpert at ADLM 2026	0.82 / 0.74 / 0.56	no — Roche/Cepheid industry context, not vendor-anchored

Synthesis result

• No new vendor-anchored evidence — every query's top hit is either (a) application/organoid-level without naming Robin's 4 vendors, (b) a re-mention of an item already in the 17:38 or 18:07 pull, or (c) an unrelated industry/competitor brand (Roche, Cepheid, 10x, Cellares, Massive Bio, CCDx).
• AcroCyte ARPA-H reappears at 0.617 (up from 0.215 in the 18:07 pull). Same item, stronger score — the existing /themes.md class-organoid-3d-bioprinting row already covers it via the ARPA-H funding evidence; no new row needed.
• Tavily answer-text vendor mis-attribution continues. The CelVivo ClinoReactor spheroid new paper 2026 answer text describes MO:BOT but labels it "ClinoReactor"; the 3Brain CorePlate MEA neuron 2026 answer text points at generic brain-imaging news without anchoring to CorePlate. Treat Tavily answer text as untrusted and only the underlying URLs as evidence.
• Dropped lanes (vs. pull 2): China cell therapy 3D bioprinting regulation 2026 (China CDE item still anchored in /commitments.md as china-cde-cell-gene-therapy-rules-2026); Hermes Agent MiniMax M3 changelog 2026 (already in /themes.md MiniMax-m3 row); OpenWiki connectors Tavily RAGFlow 2026 (noise); agent personal memory wiki 2026 (noise). Existing rows on /themes.md and /commitments.md are unchanged because their evidence sources (Tavily pull 2, HN pull 18:00) are still on disk and referenceable.

Coverage note for next update

The China CDE regulatory lane is no longer being refreshed on every Tavily pull. The existing /commitments.md item pins it as source-backed with one credible cisema.com source. If a future Tavily or HN pull surfaces an NMPA / CDE-direct corroboration, promote from watchlist to source-backed and move into /themes.md as a confirmed row.